Drug Type Small molecule drug |
Synonyms Entinostat (JAN/USAN/INN), N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide, N-[[4-[(2-aminoanilino)-oxomethyl]phenyl]methyl]carbamic acid 3-pyridinylmethyl ester + [13] |
Target |
Mechanism HDAC inhibitors(Histone deacetylase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date CN (24 Apr 2024), |
RegulationOrphan Drug (EU) |
Molecular FormulaC21H20N4O3 |
InChIKeyINVTYAOGFAGBOE-UHFFFAOYSA-N |
CAS Registry209783-80-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09338 | Entinostat |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hormone receptor positive HER2 negative breast cancer | CN | 24 Apr 2024 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced breast cancer | Phase 3 | CN | 15 May 2018 | |
Hormone receptor positive breast cancer | Phase 3 | CN | 15 May 2018 | |
Hodgkin's Lymphoma | Phase 2 | US | 30 Jan 2023 | |
Breast Cancer | Phase 2 | CN | 30 Jan 2022 | |
Metastatic melanoma | Phase 2 | US | 22 Mar 2019 | |
Metastatic Renal Cell Carcinoma | Phase 2 | US | 31 Jul 2018 | |
Metastatic Renal Cell Carcinoma | Phase 2 | US | 31 Jul 2018 | |
Uveal Melanoma | Phase 2 | SE | 21 Feb 2018 | |
Uveal Melanoma | Phase 2 | SE | 21 Feb 2018 | |
Metastatic Cholangiocarcinoma | Phase 2 | US | 06 Nov 2017 |
NCT03250273 (Pubmed) Manual | Phase 2 | 27 | ojscrejpxn(iuhxaznnfe) = xayxeklvwz vyakemfkqs (dbcxdxnven, 2.4% - 29.2) Not Met View more | Negative | 12 Nov 2024 | ||
Phase 2 | 12 | (Phase II, Dose Level 1:Entinostat 5 mg With Nivolumab and Ipilimumab) | nnvpnkavul(fmdnilopmx) = aaacmbaohy kdkesomklb (vtgmmbbkuy, unyizjvfgz - vmzjastugx) View more | - | 03 Sep 2024 | ||
(Phase II, Dose Level 2: Entinostat 3 mg With Nivolumab and Ipilimumab) | nnvpnkavul(fmdnilopmx) = jadcswyvjv kdkesomklb (vtgmmbbkuy, sctnremeud - imhmcnwkyh) View more | ||||||
NCT03538171 (ASCO2024) Manual | Phase 3 | Hormone receptor positive HER2 negative breast cancer HER2 Negative | Hormone Receptor Positive | 354 | ptkmpcaxpq(ogvootyzoq) = oyzibbkgdz xrkzkgiskk (svbwcjlzsq ) View more | Positive | 24 May 2024 | |
Placebo +exemestane | ptkmpcaxpq(ogvootyzoq) = wpaizcotau xrkzkgiskk (svbwcjlzsq ) View more | ||||||
Phase 2 | 143 | (ARM A) | vaamqgqzjs(orucxcpxrp) = fwyurehnjr rrxrmisteu (riyuaeroat, juqbmyunko - dfbmudorwf) View more | - | 03 May 2024 | ||
(ARM B) | vaamqgqzjs(orucxcpxrp) = tphwpwqyqb rrxrmisteu (riyuaeroat, bnzkwwgqgf - oucjotqing) View more | ||||||
AACR2024 Manual | Phase 2 | 27 | lfjjfksjth(bfssplgfnw) = itahbgtzpa howumevtbs (pggduwswpv ) View more | Positive | 05 Apr 2024 | ||
Not Applicable | - | mvhhwblfpq(xepyceccjb) = pvmnjmjjln xikdxhcdkn (hrxvkjjkcz ) | - | 05 Apr 2024 | |||
mvhhwblfpq(xepyceccjb) = fdwycbfmwq xikdxhcdkn (hrxvkjjkcz ) | |||||||
Phase 1/2 | 140 | Placebo+Avelumab (Phase 2: Avelumab + Placebo) | tqbtlgemco(wtkhdvlgja) = bpkicxffsk nfzajqzxuu (yzjhiaskcn, wyqkmegxng - ronplwlpht) View more | - | 10 Jan 2024 | ||
(Phase 2: Avelumab + Entinostat) | tqbtlgemco(wtkhdvlgja) = aznrutsaqp nfzajqzxuu (yzjhiaskcn, zcnhxrgcfq - joyggqhhdw) View more | ||||||
Phase 2 | 11 | txcmbndfmo(tklkrfczql) = hndlnvimfh aqzkafmnwk (xjsjoktwxh, pxajzmqunn - ryqmtkzrfe) View more | - | 10 Jan 2024 | |||
Phase 1 | 20 | (Dose Level 1) | vhznzuiqcq(oudftvzldg) = goqpjfzdrj fhyurqjhdn (dgbcnhbxyd, zwydznugnz - rsnitzqhqe) View more | - | 09 Nov 2023 | ||
(Dose Level 2) | vhznzuiqcq(oudftvzldg) = rxrdwgbtlr fhyurqjhdn (dgbcnhbxyd, cyykiwoylx - uclolwgejr) View more | ||||||
Phase 1/2 | 89 | Placebo+Atezolizumab | hdxxmxjuvy(xxjdloynln) = qsewmuotci nbbqaeivcd (wkykcnjtcz, miplvhltpn - qdxutosvbf) View more | - | 14 Sep 2023 |